Shen Yi, Zhang Jiayu, Qiu Xiuyue
School of Nursing, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310051, China.
J Clin Transl Endocrinol. 2025 Aug 19;41:100415. doi: 10.1016/j.jcte.2025.100415. eCollection 2025 Sep.
The cardiometabolic index (CMI) is a reliable marker used to assess the degree of obesity and lipid metabolism disorders in individuals. Emerging evidence indicates that disorders of lipid metabolism and sarcopenia share a common pathophysiologic basis. However, few studies have investigated the association between CMI and sarcopenia. Therefore, this study aimed to find the possible correlation between CMI and sarcopenia.
This study used cross-sectional research methods to investigate data on CMI, sarcopenia, and other covariates among participants in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2018. We explored the relationship between CMI and sarcopenia through multivariate linear and logistic regression, and we performed sensitivity and subgroup analyses. Also, receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were utilized to evaluate the performance of CMI in identifying sarcopenia.
Of the 4,808 adults aged 20 to 59 included in this study, 428 (8.90 %) were identified as having sarcopenia. A significant nonlinear association between CMI and sarcopenia was demonstrated in a generalized additive model (GAM). After inclusion of all covariates, CMI showed a significant association with the prevalence of sarcopenia (OR = 1.173(1.086-1.267), < 0.001). CMI got an AUC of 0.69 in identifying sarcopenia. Finally, subgroup analyses showed that the association between CMI and sarcopenia was particularly pronounced in individuals who differed in marital status, poverty-to-income ratio, alcohol consumption, patients without diabetes, and patients with hypertension ( < 0.05).
This study demonstrated that an elevated CMI was associated with an increased prevalence of sarcopenia. The finding suggests that CMI could serve as a potential marker for sarcopenia, highlighting the need for further research to explore the relationship between dyslipidemia and sarcopenia.
心脏代谢指数(CMI)是用于评估个体肥胖程度和脂质代谢紊乱的可靠指标。新出现的证据表明,脂质代谢紊乱和肌肉减少症具有共同的病理生理基础。然而,很少有研究调查CMI与肌肉减少症之间的关联。因此,本研究旨在寻找CMI与肌肉减少症之间可能的相关性。
本研究采用横断面研究方法,调查了2011年至2018年美国国家健康与营养检查调查(NHANES)参与者中CMI、肌肉减少症及其他协变量的数据。我们通过多变量线性和逻辑回归探讨了CMI与肌肉减少症之间的关系,并进行了敏感性和亚组分析。此外,利用受试者工作特征(ROC)曲线分析和曲线下面积(AUC)评估CMI在识别肌肉减少症方面的表现。
本研究纳入的4808名20至59岁成年人中,428人(8.90%)被确定患有肌肉减少症。广义相加模型(GAM)显示CMI与肌肉减少症之间存在显著的非线性关联。纳入所有协变量后,CMI与肌肉减少症的患病率显著相关(OR = 1.173(1.086 - 1.267),P < 0.001)。CMI在识别肌肉减少症方面的AUC为0.69。最后,亚组分析表明,CMI与肌肉减少症之间的关联在婚姻状况、贫困收入比、饮酒情况、无糖尿病患者和高血压患者中尤为明显(P < 0.05)。
本研究表明,CMI升高与肌肉减少症患病率增加有关。这一发现表明CMI可能作为肌肉减少症的潜在标志物,凸显了进一步研究探索血脂异常与肌肉减少症之间关系的必要性。